Sandbox southuniversity6: Difference between revisions

← Older edit Newer edit →

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Arthur Cox

@@ Line 8: / Line 8: @@
 [[Image:l731988_keto_enol.png|left|500px|keto-enol tautomerism of L-731,988 a beta-diketo acid integrase inhibitor]]
-The functional groups proposed for the [[pharmacophore]] of the DKAs includes a aromatic ring located a certain distance from hydrogen bond donating and accepting groups. Looking at the enol tautomer of L-731,988, how many hydrogen bond donors do you see?
+The functional groups proposed for the [[pharmacophore]] of the DKAs includes a aromatic ring located a certain distance from a group of hydrogen bond donating and accepting groups. The orientation of a hydrogen bond donor group relative to 2 required hydrogen bond acceptors is very important for activity.
-[[Image:isentress.png|left|300px|raltegravir (isentress)]]
+<quiz display=simple>
-Compare the structure of raltegravir (Isentress)to that of the prototype DKA shown above. Can you see a hydrophobic group at one end of the molecule, with hydrogen bond donor, acceptor, and donor functional groups next to each other?
+{Looking at the enol tautomer of L-731,988, how many hydrogen bond donors do you see?
+|type="()"}
++ 3
+- 1
+- 2
+</quiz>
-<StructureSection load='RLT' size='500' side='right' caption='Structure of the first HIV integrase inhibitor to market, raltegravir (PDB entry [[RLT]])' scene=''>The structure to the left is the first HIV integrase that has made it's way to market, raltegravir (Isentress).
+<quiz display=simple>
+{Looking at the enol tautomer of L-731,988, how many hydrogen bond donors do you see?
+|type="()"}
++ 3
+|| That is correct.
+- Distractor.
+|| Feedback for distractor.
+- Distractor.
+|| Feedback for distractor.
+- Distractor.
+|| Feedback for distractor.
+</quiz>
+[[Image:isentress_view2.png|left|200px|raltegravir (isentress)]]
+The structure to the right is the first HIV integrase inhibitor approved in the US, raltegravir (Isentress). Compare its structure to that of the prototype DKA shown above. Can you see a hydrophobic group at one end of the molecule, with hydrogen bond donor, acceptor, and donor functional groups next to each other?
+<StructureSection load='RLT' size='500' side='right' caption='Structure of the first HIV integrase inhibitor to market, raltegravir (PDB entry [[RLT]])' scene=''>The presence of a hydrogen bond .
 </StructureSection>